Form 4 for NAGE Niagen Bioscience, Inc.
Accepted 2024-08-26 00:00:00 ET · period of report 2024-08-23 · accession 0001628280-24-038470 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-08-26 | 2024-08-23 | NAGE | Patrick Kristin | Dir | S - Sale+OE | $3.57 | -23.0K | 0 | -100% | -$82.1K |
| DM | 2024-08-26 | 2024-08-23 | NAGE | Patrick Kristin | Dir | M - OptEx | $1.67 | +23.0K | 3,000 | New | +$38.3K |
| DM | 2024-08-26 | 2024-08-23 | NAGE | Patrick Kristin | Dir | M - OptEx | $0.00 | -23.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-23 | S | D | 23,000 | $3.57 | 0 | D | — | — | (F1) The weighted average sale price for the transaction reported was $3.57, and the range of prices were between $3.52 and $3.64. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 2 | Common | Common Stock | 2024-08-23 | M | A | 20,000 | $1.67 | 23,000 | D | — | — | |
| 3 | Common | Common Stock | 2024-08-23 | M | A | 3,000 | $1.64 | 3,000 | D | — | — | |
| 4 | Derivative | Stock Option (right to buy) | 2024-08-23 | M | D | 3,000 | $0.00 | 17,000 | D | $1.64 · 2023-06-16 to 2032-06-15 | 3,000 Common Stock | |
| 5 | Derivative | Stock Option (right to buy) | 2024-08-23 | M | D | 20,000 | $0.00 | 0 | D | $1.67 · 2024-06-15 to 2033-06-14 | 20,000 Common Stock |